Vaxart Inc Stock Investor Sentiment

VXRT Stock  USD 0.54  0.02  3.85%   
Slightly above 60% of all Vaxart's private investors are looking to take a long position. The analysis of the overall investor sentiment regarding Vaxart Inc suggests that some traders are interested. Vaxart's investing sentiment can be driven by a variety of factors including economic data, Vaxart's earnings reports, geopolitical events, and overall market trends.
  

Vaxart Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Vaxart can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
a minute ago at bizjournals.com         
RFK Jr. pauses Peninsula companys oral Covid vaccine clinical trial
bizjournals News
20 hours ago at www.macroaxis.com         
Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
Macroaxis News
a day ago at www.macroaxis.com         
Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
Macroaxis News
2 days ago at www.macroaxis.com         
Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
Macroaxis News
3 days ago at gurufocus.com         
Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20
Gurufocus Stories at Macroaxis
3 days ago at gurufocus.com         
Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
few days ago at www.macroaxis.com         
Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
Macroaxis News
few days ago at finance.yahoo.com         
Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate
Yahoo News
few days ago at gurufocus.com         
Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
few days ago at www.macroaxis.com         
Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
Macroaxis News
six days ago at www.macroaxis.com         
Acquisition by Sean Tucker of 54157 shares of Vaxart subject to Rule 16b-3
Macroaxis News
over a week ago at www.macroaxis.com         
Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
Macroaxis News
over a week ago at www.macroaxis.com         
Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
Macroaxis News
over a week ago at zacks.com         
Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
zacks News
over a week ago at zacks.com         
Xeris Biopharma Reports Q4 Loss, Misses Revenue Estimates
zacks News
Far too much social signal, news, headlines, and media speculation about Vaxart that are available to investors today. That information is available publicly through Vaxart media outlets and privately through word of mouth or via Vaxart internal channels. However, regardless of the origin, that massive amount of Vaxart data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Vaxart news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vaxart relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vaxart's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vaxart alpha.

Vaxart Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3
12/31/2024
2
Insider Trading
01/28/2025
3
Disposition of 9242 shares by Edward Berg of Vaxart at 0.6798 subject to Rule 16b-3
01/31/2025
4
Acquisition by Cummings James F. of 90000 shares of Vaxart subject to Rule 16b-3
02/26/2025
5
Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its ...
03/05/2025
6
Acquisition by Sean Tucker of 54157 shares of Vaxart subject to Rule 16b-3
03/07/2025

Additional Tools for Vaxart Stock Analysis

When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.